Joint Clinical Trials Office
A Multi-center Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adults Patients with Hematologic Malignancies and Other Indications
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 12, 2020
Protocol for A Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 12, 2020
National Marrow Donor Program (NMDP) and Center for International Blood and Marrow Transplant Research (CIBMTR) – Research Database for Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 12, 2020
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 15, 2020
Phase I/II Dose-Escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 8, 2020
Single-Arm Phase II Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy with Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: January 13, 2021
A Pilot Study of Rimegepant in Moderate Plaque-type Psoriasis
Study Status:
Open to Enrollment
Primary Investigator:
Date: January 15, 2021
Multimodal Neuroimaging in Traumatic Brain Injury
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 16, 2021
Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Study Status:
Open to Enrollment
Primary Investigator:
Date: February 24, 2021
VMO-01C: An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 25, 2021